On June 29, 2017, kukura Laipushutai, boka I itsva mushonga chete pamwe pave JYMed uye Guangzhou Linkhealth Medical Technology Co., Ltd., wakaita zvaikosha mberi. The mushonga wacho IND chinoziviswa kwave kugamuchirwa ne CFDA.
JYMed uye Guangzhou Linkhealth Medical Technology Co., Ltd. asvika pamwe chibvumirano muna 2016 kusvika anorenda kuva chigadzirwa ichi mu China. Mhando apedza POC zvidzidzo zvekuchipatara muna EU uye kubudirira zvakanaka kuchengeteka uye nokuregererwa prices. Vose FDA uye EMA vanoziva kuti ichi rudzi ingashandiswa kunorapwa pamusoro I / II mutsetse, uye nharungano achapiwa kuzorodzwa uye kurapwa varwere mwero maronda colitis mu Follow zvekuchipatara nemiedzo CFDA.
Maronda colitis (UC) iri chirwere, asiri dzakananga anogumbura chirwere kuti rikaitika mugaranhoko uye muura. Maererano nenhamba, kuitika mwero UC ndiyo 1,2 kusvika 20.3 nyaya / 100,000 munhu pagore uye kuwanda UC ndiyo 7.6 kuti 246,0 nyaya / vanhu 10,000 pagore. Kuitika UC zvikuru nevanhu vechiduku. The UC musika ane zvizhinji uye kudiwa zvinodhaka, uye acharamba tichizvibata kukura muitiro mune ramangwana. Saka kure, UC vomuzana mutsetse zvinodhaka dzinowanzotsigi- kwakavakirwa mesalazine uye hormone, uye wechipiri-mutsetse zvinodhaka zvinosanganisira immunosuppressants uye zvipenyu monoclonal antibodies. Mesalazine ane rokutengesa Vhoriyamu mabhiriyoni 1 muna China uye US $ 2 billion muUnited States muna 2015. Laipushutai ane nani mhinduro UC zviratidzo, uye ari nani kupfuura pari vomuzana mutsetse zvinodhaka. It ane chakanaka musika nani uye anotarisirwa kuti ave wokutanga-mutsetse UC zvinodhaka.
Post nguva: Mar-02-2019
